Navigation Links
Roche Diagnostics Opens State-of-the-Art Training Center in California
Date:12/7/2009

INDIANAPOLIS, Dec. 7 /PRNewswire/ -- Roche Diagnostics announced today the opening of a new west-coast customer training center in Pleasanton, California, as part of an initiative to make state-of-the-art training on diagnostic equipment more accessible to hospitals and independent laboratories on the west and east coasts. Roche has an existing training center at its headquarters in Indianapolis and is planning to open an additional facility in New Jersey in 2010.

The expansion of training centers beyond Indianapolis is intended to support Roche's goal of offering customers best-in-class service, according to Michael Tillmann, president and CEO of Roche Diagnostics North America. "Hands-on training with our products can enhance the learning experience for our customers and help them translate that knowledge into greater efficiencies and better outcomes in their own labs," he said. "Adding advanced training facilities on the west and east coasts will make it much easier for customers to access the training and accommodate the travel into their schedules."

The new Pleasanton training center, which includes three classrooms and a working laboratory, occupies approximately 5,000 square feet at an existing facility owned by Roche Molecular Systems, a division of Roche Diagnostics. The center will house the latest Roche instrumentation used for molecular diagnostics and clinical chemistry/immunochemistry testing, and will be managed by Roche's Indianapolis-based training team, which coordinates training for all U.S. customers.

"Having these new facilities will not only make it easier to provide our existing customers with training, it will also enable more potential customers to see our diagnostics solutions in operation," said Marco Casarin, Senior Vice President, Roche Services North America. "We also intend to use the centers to facilitate user group meetings, where customers can share best practices and see the potent
'/>"/>

SOURCE Roche Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to 80% ... pain can range from a dull, constant ache (chronic) to a sudden sharp pain ... steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & Regenerative ...
(Date:6/30/2015)... Las Vegas, NV (PRWEB) , ... June 30, ... ... has recently returned to the U.S. after a 5-day tour in India. ... that are currently collaborating with Trivedi Master Wellness™ and Transformational Leader/Internationally ...
(Date:6/30/2015)... CT (PRWEB) , ... June 30, 2015 , ... ... on Wednesday, June 24, 2015 amidst bright skies and inspirational words. , ... the cherished processional walk from the Glenholme building to the school’s Center for ...
(Date:6/30/2015)... ... June 30, 2015 , ... Healthy and productive interpersonal ... outcomes. According to Dr. Theo Wubbels (Professor of Education, Admissions Dean, Utrecht ... to show “all kinds of behavior when the situation asks for it.” ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson ... to Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) ... automate the workflow processes of the Revenue Cycle. , Provider XO, based in ...
Breaking Medicine News(10 mins):Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Dephinitive Systems Is Getting a New Name 2
... HealthDay Reporter , MONDAY, Jan. 23 (HealthDay News) -- Since ... questioned the safety of medical procedures used to terminate pregnancy. ... abortion is safer than carrying a baby to term. ... delivery is 8.8 deaths per 100,000, while the risk of ...
... world media, researchers, academics including several from Simon Fraser ... the Vancouver Convention Centre Feb. 16-20. , Simon Fraser University,s ... of a bell announcing the 2012 AAAS (American Association ... Aquarium yesterday. , "The AAAS conference is a must for ...
... MRI helps surgeons make more informed decisions about nerve-sparing ... new study published online in the journal Radiology ... most common cancer diagnosed in American men, according to ... prostatectomy, or removal of the prostate, is a common ...
... Jan. 24, 2012) For men diagnosed ... drug dutasteride ("Avodart") delays disease progression and initiating active ... a three-year international clinical trial led by Dr. Neil ... Network (UHN). The findings are published online ...
... Wakeling is adding to the arsenal of increasingly sophisticated ... viewing muscle activation details that have never been seen ... movement in people and animals, Wakeling has developed a ... proprietary data-processing software to scan and capture 3D maps ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Jan. ... be bad for you, a new study finds that parts of ... with others. It,s not clear how this effect of stress ... system -- which cause inflammation in the body -- have been ...
Cached Medicine News:Health News:Abortion Safer for Women Than Childbirth, Study Claims 2Health News:Abortion Safer for Women Than Childbirth, Study Claims 3Health News:SFU hits hot buttons at 2012 AAAS conference 2Health News:SFU hits hot buttons at 2012 AAAS conference 3Health News:Preoperative MRI may reduce risk of nerve damage in prostate cancer surgeries 2Health News:Prostate cancer study proves drug delays disease progression 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3
... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
Optimal solution for normal acetabulum....
Optimal solution for normal acetabulum....
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
Medicine Products: